Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, α2-adrenergic and D2 receptors in the rat brain

European Neuropsychopharmacology

Volumn 19, Issue 3, 2009, Pages 177-187

  Ghanbari, Ramez ^a   El Mansari, Mostafa ^a   Shahid, Mohammed ^b   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asenapine; Dopamine; Electrophysiology; Norepinephrine; Schizophrenia; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA 2 ADRENERGIC RECEPTOR; APOMORPHINE; ASENAPINE; CLONIDINE; DOPAMINE 2 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG RECEPTOR BINDING; HIPPOCAMPUS; LOCUS CERULEUS; MALE; MICROIONTOPHORESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; VENTRAL TEGMENTUM;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ACTION POTENTIALS; AMPHETAMINES; ANIMALS; APOMORPHINE; BRAIN; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D2;

EID: 58949100862     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.11.001     Document Type: Article

References (58)

1. Aghajanian G.K. Feedback regulation of central monoaminergic neurons: evidence from single-cell recording studies. Essays Neurochem. Neuropharmacol. 3 (1978) 1-32
2. Aghajanian G.K., and Vandermaelen C.P. Intracellular identification of central noradrenergic and serotonergic neurons by a new double labeling procedure. J. Neurosci. 2 (1982) 1786-1792
3. Aston-Jones G., Akaoka H., Charléty P., and Chouvet G. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J. Neurosci. 11 (1991) 760-769
4. Blier P. Atypical antipsychotics for mood and anxiety disorders: safe and effective adjuncts?. J. Psychiatry Neurosci. 30 (2005) 232-233
5. Chaudhry I.B., Husain N., Khan S., Badshah S., Deakin B., and Kapur S. Amoxapine as an antipsychotic: comparative study versus haloperidol. J. Clin. Psychopharmacol. 27 (2007) 575-581
6. Conley R.R., and Kelly D.L. Current status of antipsychotic treatment. Curr. Drug Targets CNS Neurol. Disord. 2 (2002) 123-128
7. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 (2003) 553-564
8. Dawe G.S., Huff K.D., Vandergriff J.L., Sharp T., O'Neill M.J., and Rasmussen K. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol. Psychiatry 50 (2001) 510-520
9. Diaz-Mataix L., Scorza M.C., Bortolozzi A., Toth M., Celada P., and Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25 (2005) 10831-10843
10. Dong J., and Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 155 (2001) 52-57
11. Dremencov E., El Mansari M., and Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol. Psychiatry 61 (2007) 671-678
12. Dremencov E., El Mansari M., and Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 194 (2007) 63-72
13. Franberg O., Wiker C., Marcus M.M., Konradsson A., Jardemark K., Schilstrom B., Shahid M., Wong E.H., and Svensson T.H. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl.) 196 (2008) 417-429
14. Freedman J.E., and Aghajanian G.K. Idazoxan (RX 781094) selectively antagonizes alpha 2-adrenoceptors on rat central neurons. Eur. J. Pharmacol. 105 (1984) 265-272
15. Garris P.A., Ciolkowski E.L., Pastore P., and Wightman R.M. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J. Neurosci. 14 (1994) 6084-6093
16. Gartside S.E., Hajos-Korcsok E., Bagdy E., Harsing Jr. L.G., Sharp T., and Hajos M. Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience 98 (2000) 295-300
17. Ghanbari, R., El Mansari, M., Blier, P., in press. Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons. J. Psychopharmacol. doi:10.1177/0269881108095714.
18. Gonon F.G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24 (1988) 9-28
19. Grace A.A., and Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons. Neuroscience 10 (1983) 301-348
20. Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci. 4 (1984) 2877-2890
21. Guiard B.P., El Mansari M., Merali Z., and Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int. J. Neuropsychopharmacol. 11 (2008) 625-639
22. Haddjeri N., and Blier P. Effects of sustained (+/-)pindolol administration on serotonin neurotransmission in rats. J. Psychiatry Neurosci. 25 (2000) 378-388
23. Haddjeri N., de Montigny C., and Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. Br. J. Pharmacol. 120 (1997) 865-875
24. Haddjeri N., de Montigny C., and Blier P. Modulation of the firing activity of rat serotonin and noradrenaline neurons by (+/-)pindolol. Biol. Psychiatry 45 (1999) 1163-1169
25. Haddjeri N., Lavoie N., and Blier P. Electrophysiological evidence for the tonic activation of 5-HT(1A) autoreceptors in the rat dorsal raphe nucleus. Neuropsychopharmacology 29 (2004) 1800-1806
26. Hajos M., and Sharp T. Burst-firing activity of presumed 5-HT neurones of the rat dorsal raphe nucleus: electrophysiological analysis by antidromic stimulation. Brain Res. 740 (1996) 162-168
27. Hatanaka K., Yatsugi S., and Yamaguchi T. Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex. Eur. J. Pharmacol. 395 (2000) 31-36
28. Hardebo J.E. Influence of impulse pattern on noradrenaline release from sympathetic nerves in cerebral and some peripheral vessels. Acta. Physiol. Scand. 144 (1992) 333-339
29. Hertel P., Nomikos G.G., and Svensson T.H. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br. J. Pharmacol. 122 (1997) 1639-1646
30. Huang M., Li Z., Dai J., Shahid M., Wong E.H., and Meltzer H.Y. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 33 (2008) 2934-2945
31. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 (2001) 1521-1531
32. Ichikawa J., Li Z., Dai J., and Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 956 (2002) 349-357
33. Kandel E.R., and Spencer W.A. Electrophysiology of hippocampal neurons. II. After-potentials and repetitive firing. J. Neurophysiol. 24 (1961) 243-259
34. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45 (1988) 789-796
35. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J. Clin. Psychiatry 64 suppl 12 (2003) 5-19
36. Kapur S., and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1081-1090
37. Kawahara Y., Kawahara H., Kaneko F., and Tanaka M. Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology (Berl) 194 (2007) 73-81
38. Litman R.E., Su T.P., Potter W.Z., Hong W.W., and Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry 168 (1996) 571-579
39. McFadden W., Calabrese J.R., and McCoy R. Double-blind, placebo-controlled study of quetiapine in bipolar depression. Int. J. Psychopharmacol. 7 suppl 1 (2004) S330
40. McIntyre R.S., Hirschfeld R., Alphs L., Cohen M., Macek T., and P. J. Randomized, placebo-controlled studies of asenapine in the treatment of acute mania in bipolar I disorder. Presented at: 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; February 3-7, 2008; Montreux, Switzerland (2008)
41. Meltzer H.Y. Atypical antipsychotic drugs. In: bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The fourth generation of progress (1995), Raven Press, New York 1277-1286
42. Montgomery S.A., Rasmussen J.G., and Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int. Clin. Psychopharmacol. 8 (1993) 181-188
43. Nemeroff C.B. Use of atypical antipsychotics in refractory depression and anxiety. J. Clin. Psychiatry 66 suppl 8 (2005) 13-21
44. Newman-Tancredi A., Chaput C., Verriele L., and Millan M.J. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 35 (1996) 119-121
45. Newman-Tancredi A., Gavaudan S., Conte C., Chaput C., Touzard M., Verriele L., Audinot V., and Millan M.J. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur. J. Pharmacol 355 (1998) 245-256
46. Papakostas G.I., Petersen T.J., Kinrys G., Burns A.M., Worthington J.J., Alpert J.E., Fava M., and Nierenberg A.A. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry 66 (2005) 1326-1330
47. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., and Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch. Gen. Psychiatry 49 (1992) 345-353
48. Potkin S.G., Cohen M., and Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J. Clin. Psychiatry 68 (2007) 1492-1500
49. Ranck J.B. Behavioral correlates and firing repertoires of neurons in the dorsal hippocampal formation and septum of unrestrained rats. In: Isaacson L.R. (Ed). The hippocampus (1975), Plenum Press, New York 207-244
50. Rollema H., Lu Y., Schmidt A.W., and Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol. 338 (1997) R3-5
51. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124 (1996) 57-73
52. Shahid M., Walker G.B., Zorn S.H., and Wong E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. (2008) (Electronic Publication ahead of print)
53. Simon J.S., and Nemeroff C.B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry 66 (2005) 1216-1220
54. Sprouse J.S., Reynolds L.S., Braselton J.P., Rollema H., and Zorn S.H. Comparison of the novel antipsychotic ziprazidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 21 (1999) 622-631
55. Szabo S.T., and Blier P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J. Pharmacol. Exp. Ther. 302 (2002) 983-991
56. Szabo S.T., de Montigny C., and Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br. J. Pharmacol. 126 (1999) 568-571
57. Stark A.D., Jordan S., Allers K.A., Bertekap R.L., Chen R., Mistry Kannan T., Molski T.F., Yocca F.D., Sharp T., Kikuchi T., and Burris K.D. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 190 (2007) 373-382
58. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., and Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60 (2003) 1079-1088